#1 Clinical Trials Search in Europe

Total-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)

1 1 1 1

What is this study about?

This clinical trial is being done in post-COVID syndrome (also called long COVID), a condition in which symptoms continue after a COVID-19 infection. The study uses flutemetamol (18F), a radioactive tracer given into a vein, to help look for tiny blood clots that contain a protein called amyloid. The purpose of the study is to see whether these amyloid-containing microclots can be seen and measured in people with post-COVID syndrome compared with control participants.

During the study, participants receive flutemetamol (18F) and then undergo a PET scan, which is an imaging test that shows where the tracer goes in the body. Some participants may also have a MRI scan, which uses magnetic fields to create pictures of the brain. Blood samples and symptom questionnaires are also used to gather more information about the amount of microclots and the presence and severity of symptoms.

The study is expected to run over several months. It focuses on whether this imaging method can show differences in amyloid-containing microclots between people with post-COVID syndrome and controls, and whether these findings relate to symptoms and brain scan results.

1 study entry and first trial visit

After you join the study, you take part in the first trial visit. During this stage, the study uses flutemetamol (18f), which is given as an intravenous dose. This means it is put into a vein through a needle. The source data does not give a dose amount.

The trial uses a total-body dynamic pet scan. pet means positron emission tomography, which is a scan that shows where the study drug is found in your body. The scan is used to measure how much of the study drug binds in different parts of the body.

2 imaging and measurement stage

After the injection, you undergo the total-body dynamic pet scan. This scan is used to look for and measure amyloid-containing microclots. Amyloid is a type of protein, and microclots are very small blood clots.

The scan measures how the study drug behaves in your body over time. The main measurements are reported as volume of distribution or non-displaceable binding potential. These are technical ways of describing how much of the study drug is held in body tissues.

3 blood testing stage

You provide blood samples so the study can measure the amount of amyloid-containing microclots in your blood. The study records both the size and the quantity of these microclots.

No blood test timing, number of samples, or duration of collection is specified in the source data.

4 questionnaire stage

You complete questionnaires about the presence and severity of your post-covid symptoms. These questionnaires ask how symptoms are affecting you and how severe they are.

The source data does not provide the number of questionnaires, the exact timing, or how long this stage lasts.

5 mri stage

You undergo mri, which means magnetic resonance imaging. This is a scan used to look at the structure and function of the brain.

The study uses the mri results to measure brain structure and function. The source data does not state the number of scans or the timing of this stage.

6 study completion

After the planned scan, blood testing, questionnaires, and mri are finished, your participation in the trial ends.

The source data gives the estimated study period as starting on 2026-03-02 and ending on 2026-12-31.

Who Can Join the Study?

  • The person must have had symptomatic COVID-19, meaning they had symptoms during the infection, and the infection must have been confirmed by a positive PCR test for SARS-CoV-2 (a laboratory test that detects the virus that causes COVID-19).
  • The person must be at least 12 months past the time they were diagnosed with COVID-19.
  • The person must be between 40 and 65 years old.
  • The person must have enough command of the Dutch language to understand the study procedures and instructions.
  • The person must be able to undergo the PET scan procedures, where PET stands for positron emission tomography, a type of imaging test that shows activity inside the body.

Who Cannot Join the Study?

  • Having another medical condition linked to amyloid formation (a buildup of an abnormal protein called amyloid), such as diabetes, rheumatoid arthritis (a long-term disease that causes joint inflammation), or neurodegenerative disorders (diseases that damage the brain or nerves, such as some forms of dementia).
  • Being unable to have the scanning tests because of claustrophobia (fear of enclosed spaces), severe back pain, or trypanophobia (fear of needles).
  • Using anti-coagulant drugs (medicines that reduce blood clotting, often called blood thinners).
  • Being a female who can become pregnant and who is not surgically sterile (permanently unable to have children after surgery), is not avoiding sexual activity, or is not using a reliable method of contraception (a dependable way to prevent pregnancy).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Adfpaljim Uwn Amsterdam The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not yet recruiting
02.03.2026

Trial locations

Investigated drugs:

Flutemetamol (18F) is a PET imaging tracer used in this study to help doctors see and measure amyloid-containing microclots in the body. It is given through a vein and works as a special marker that can attach to certain targets in the blood vessels and tissues, allowing the scan to show where these microclots may be present and how much there is. This helps researchers compare post-COVID patients with healthy controls.

Investigated diseases:

Post-COVID-19 syndrome – A condition that develops after a person has had COVID-19 and continues for weeks or months beyond the initial infection. It can involve a wide range of ongoing symptoms that may change over time, with some symptoms gradually improving while others persist or come and go.

Trial ID:
2025-522348-42-00
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study on Metformin and Colchicine for Patients with Long COVID Symptoms

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • A Study of Fluvoxamine for Reducing Fatigue in Patients with Post-COVID Condition

    Recruiting

    3 1 1
    Investigated diseases:
    The Netherlands